Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Retained Earnings: 2022-2024

Historic Retained Earnings for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to -$602.3 million.

  • Taysha Gene Therapies' Retained Earnings fell 17.13% to -$683.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$683.4 million, marking a year-over-year decrease of 17.13%. This contributed to the annual value of -$602.3 million for FY2024, which is 17.41% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported Retained Earnings of -$602.3 million as of FY2024, which was down 17.41% from -$513.0 million recorded in FY2023.
  • Taysha Gene Therapies' 5-year Retained Earnings high stood at -$401.4 million for FY2022, and its period low was -$602.3 million during FY2024.
  • Its 3-year average for Retained Earnings is -$505.6 million, with a median of -$513.0 million in 2023.
  • Data for Taysha Gene Therapies' Retained Earnings shows a maximum YoY declined of 27.79% (in 2023) over the last 5 years.
  • Over the past 3 years, Taysha Gene Therapies' Retained Earnings (Yearly) stood at -$401.4 million in 2022, then fell by 27.79% to -$513.0 million in 2023, then decreased by 17.41% to -$602.3 million in 2024.